Podcasts about Cart

En este Smollop de El Dollop, conocemos la increíble historia de Frank “Woody” Woodbine, un empresario, cartógrafo y promotor de caminos que comenzó ayudando a automovilistas varados y terminó contribuyendo al desarrollo de la señalización de carreteras en Estados Unidos. También acompañó a la famosa “Chica del Trigo de Kansas” en una gira nacional, codeándose con políticos y funcionarios… hasta que algo comenzó a romperse. Una historia que empieza como “este señor era bastante útil para la sociedad” y termina en “¿por qué está vestido así y por qué le gustan tanto los pollos?” Síguenos y visita nuestro sitio oficial: https://www.instagram.com/eldollop https://twitter.com/eldollop https://www.facebook.com/eldolloppodcast Los Dollops: @ninguneduardo @bryanthemachine http://eldollop.com Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. dermatology drugs, biologics, andJAK inhibitors - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: Latest #s: EHR estimates from 6 large US medical systems, estimated prevalence of autoimmune Dz (AID) to be 15 million (4.6% US population); 34% have 2+ AID. Women have 2x risk. Sex ratio of 1.7:1 F:M. https://buff.ly/fYgRfZ0 POETYK PsA-1: Deucravacitinib in Biologic-Naïve PsA POETYK PsA-1 trial tested the disease modifying efficacy of deucravacitinib, a tyrosine kinase 2 (TYK2) inhibitor, in PsA patients and was shown to be superior vs to placebo for clinical responses, patient-reported outcomes, https://t.co/VjwpCVKPz0 MoonLake announced positive phase 3 data from its IZAR-1 RCT using its dual A/F IL-17 inhibitor sonelokimab, showing significant responses at week 16: 66% ACR20, 42% ACR50, 41% minimal disease activity (MDA), & 61% PASI90 at week 16. a 2nd IZAR-2 PsA RCT is in progress https://t.co/eX0cxekRKG British Dermatology Biologics registry (BADBIR) 18976 #PSO pts had incidence serious infxns (SIE) 28 SEI/1000 Pt-Yrs; higher if they had prior infxn (79/1000 PYs). SIE signif lower w/ RIZankizumab (HR 0.74-.80) vs BROAD, ETN, other standards Rxs. SIE deaths rare (1.81/1000 PYs) https://t.co/GTr3DLCVXs 39 studies compared Juvenile systemic sclerosis (jSSc) & adult SSc. 935 jSSc vs 15,451 aSSc pts; jSSc had more diffuse cutaneous dz (70% vs 41%), more overlap myositis (33% vs. 5%), arthritis (33% vs 18%), digital ulcers (51% vs 20%), less renal crisis (0% vs 6%) & lower mortality jSSc (7.7% vs. 20.4%) https://t.co/vflarmwSyv Italian SPRING cohort of #SSc pts found only 5.3% (of 1689 pts) without the typical scleroderma pattern on nailfold change by NVC. They had milder dz, with less vascular dz (pitting scars 33 vs 48%), telangiectasias (52 vs 74%), calcinosis 3.4 vs 12%) & higher DLCOs at 12, 24, https://t.co/AoNAhVYfII Review of CAR-T 29 trials in systemic sclerosis (SSc): 27/29 target CD19 (other CD20, BCMA), 20/29 autologous. Only 2 RCTs; 1 w/ RTX comparator. Most included CREST. Schetts largest series had 6 dcSSc w/ skin/lung improvements. Need fewer & larger multicenter RCTs https://t.co/Me28HbaFhR SLE & Dermatomyositis rashes maybe classically red or violaceous in Whites,but different in people of color, where erythema often appears brown/violaceous, Gottron papules can be mistaken for "dry skin." This delays dx, especially in anti-MDA5+ RP-ILD, where rash may be the https://t.co/Savx5IOTcG Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - the 1st therapy approved for the most common form of vitiligo. Based on positive results from the Phase 3 Viti-Up trials https://t.co/MMv5LjZclQ 3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo

Andrew Vontz has been an endurance athlete for 38 years. In March doctors found a tumor running from his the cavity between his lungs up across his neck that had displaced his carotid artery and was crushing his trachea. — This is the cancer episode. Andrew is five months into treatment for diffuse large B-cell lymphoma. He has been through six rounds of chemo, a cytokine release storm, multiple hospitalizations, and in September will go to Dana Farber Cancer Institute for three weeks to get CAR T genetic therapy. He talks about how he discovered he had cancer, living with uncertainty, going through chemo, what thirty-eight years of endurance sport did and did not prepare him for, and how listening to his body has guided his cancer experience. — Guiding the conversation is the titan of entrepreneurship, leadership development, and finance Shannon Jones, who teaches Entrepreneurship Through Acquisition at the University of Colorado Boulder's Leeds School of Business, writes the TranscendenCEO newsletter, and was a two-sport Division I athlete. Shannon joined Andrew on a previous episode to talk about building and winding down The Better Lab. — Thank you to everyone in this community who has reached out to provide positivity, prayers, encouragement, and support during this experience. — Recorded August 21, 2026, three days after Andrew's sixth round of chemo. — The media landscape has changed. Scripted is out. Real is in. Being a great podcast guest or host and being able to operate in dynamic unscripted contexts isn't optional. It's now a mandatory skill for senior leaders and doing it well isn't easy. That's why Andrew Vontz started __https://www.onerealvoice.com/__ to help industry leaders thrive on podcasts, panels and the internal and external high-stakes open-ended conversations where reputations are built and business is won. — When you're ready to be great, DM __https://www.instagram.com/hardwaypod__ or reach out to hello@onerealvoice.com. — To support this work, become a paid subscriber to the Choose the Hard Way Substack at __https://alwaysthehardway.substack.com__. — With over $1 trillion in transactions to date, Blockchain.com is your trusted partner on your crypto journey. Go to Blockchain.com to get started today no experience required. — Lauf is the Apple of bike design and they make elegant products that just work better than everything else. Check them out at __https://www.laufcycles.com__. — Thank you to Sunlighten infrared saunas for helping make it possible for my family to have an mPulse sauna. Being able to relax and recover in our mPulse sauna when possible between treatments is healing and feels like a luxury. I'm grateful for your support. Sunlighten: __https://www.sunlighten.com/__ — Thank you to Peloton of "come on Peloton, you got this" fame for following my cancer experience and surprising me with a Peloton Tread. Being able to go to the garage and move is huge for me, and Molly, especially on days when I'm too wiped to be able to take the dogs out. It's a next level treadmill and it takes me places. Peloton: __https://www.onepeloton.com/__ — Andrew Vontz's Choose the Hard Way newsletter: __https://alwaysthehardway.substack.com/__ — One Real Voice: __https://www.onerealvoice.com/__ — Instagram: __https://www.instagram.com/hardwaypod__ — LinkedIn: __https://www.linkedin.com/in/andrewvontz/__ — Shannon Jones's TranscendenCEO newsletter: __https://transcendenceo.substack.com/__ — Follow Shannon Jones on LinkedIn: __https://www.linkedin.com/in/wshannonjones/__ -  

Drs. Ghia and Scarfò discuss how CAR T-cell therapy is emerging as a powerful option for high-risk CLL and Richter transformation, especially in patients who have failed BTK and BCL-2 inhibitors. They stress that achieving deep remissions, choosing the right patients, and referring early to specialized centers are critical to improving outcomes.

This month, the gals welcome Bridget Todd, author and host of There Are No Girls On the Internet, to discuss a doped-up dog, a most unwelcome hospital visitor, the worst best friend, sneeze-farts, beginner porn, an update from the Methodists, and yet another victim of Hobby Lobby. Tune in now for Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

We Like Shooting We Like Shooting - Ep 676 August 17, 2026 Presented by This episode of We Like Shooting is brought to you by: Foxtrot Mike (Code: WLSISLIFE) C&G Holsters (Code: WLSISLIFE) Gideon Optics (Code: WLSISLIFE) Midwest Industries (Code: WLSISLIFE) Blue Alpha Night Fision (Code: WLSISLIFE) Otis Technology (Code: WELIKESHOOTING15) Giveaways!! GAW   Text Dear WLS or Reviews +1 743 500 2171 Public   Show Titles   Gear Chat Note Montana Knife Company stoned goat ultrahttps://www.montanaknifecompany.com/products/stoned-goat-ultra EAA Corp. Girsan Witness2311 CMX XXX Discover the Witness2311 CMX XXX, a compact double stack 1911 with 16+1 capacity, a slim grip, firing pin block safety, and two-tone finish. The Girsan Witness2311 CMX XXX is a compact single-action 9mm pistol from EAA Corp. with 16+1 capacity using Check-Mate magazines. It features an RMSc-footprint optic-ready slide, 3.4-inch coned barrel, two-tone Cerakote finish, low-profile 3-dot sights, ambidextrous thumb safety, 4-slot Picatinny rail, and EAA limited lifetime warranty. Availability: Available for purchase via Add to Cart on eaacorp.com (no explicit stock, release date or additional retailers stated) Cost: $899 Special: Streamlined compact grip with aggressive texturing, low-profile magwell, and automatic firing pin block safety replacing traditional grip safety for 16+1 capacity without added bulk Odysee (Nick) SecondWatch FTN.6 Suppressor Pack Update: We received overwhelming feedback that people did not like the text. The intention was to save on what needed to be engraved. Since it is so unpopular, all text has been removed from the model… The FTN.6 Suppressor Pack is a downloadable set of 3D-printable files for DIY suppressors released by SecondWatch on August 15, 2026, via Odysee. It includes updated designs for rimfire, 5.56, and 300 BLK models that are described as the quietest FTN variants to date, matching or surpassing many commercial suppressors in head-to-head testing. The pack continues the FTN (Fuck The NFA) series focused on accessible, low-cost polymer printed silencers. Availability: Released August 15, 2026 on Odysee (@SecondWatch); downloadable files Special: FTN.6 Air is a very lightweight (~10.6 oz) and slim rifle suppressor using thread adapters; modular flash hider and compensator add-ons; FTN.6 Rimfire offers similar sound reduction to FTN.5 but in a smaller package Defiance Machine (Nick) Defiance Machine Deviant Comp Rifle Action Deviant COMP – The new standard for PRS competitors. The Deviant COMP refines our popular Deviant model into a purpose-built precision rifle action designed specifically for PRS competitors who demand speed, consistency, and reliability under pressure. Built with the features competitive shooters actually want, the Deviant COMP features an oversized bolt for fast cycling, an AW magazine cut compatible with both AW and AICS magazines, and guaranteed headspace for repeatable accuracy and hassle-free builds. This makes the Deviant COMP a competition-ready package that is ideal for PRS. Finished with nitride included at no additional cost, the Deviant COMP delivers premium performance at an exceptional value. Specifications Integral scope mount/rail. Integral recoil lug. Defiance swept legacy bolt design. Oversized competition bolt knob. Smooth chrome-moly bolt action with anti-bind design. Recessed bolt lugs, Mini-16 extractor, and plunger ejector. AW magazine cut. Trigger pins included. Nitride finish included. Why choose the Deviant COMP? PRS competition-ready feature set. Integral rail and recoil lug means more rigidity and reliability when it matters most. Receiver is made from once piece of pre-hardened aircraft-certified 416 stainless steel, allowing for tight manufacturing tolerances and increased performance. One-piece legacy bolt, machined to exacting tolerances required to cycle as smooth as possible. Swept bolt handle design to allow plenty of clearance with your rifle scope. Precision extraction system that significantly increases initial extraction and improves smooth bolt cycling. Need an extra bolt? Extra bolts are available when purchasing your action over the phone with our team for $495 each (includes extractor, ejector, and fire control assembly). The Deviant Comp is a purpose-built short-action bolt-action receiver from Defiance Machine, refined from the standard Deviant for PRS competitors. It is machined from a single piece of pre-hardened 416 stainless steel with an integral scope rail and recoil lug for rigidity and guaranteed headspace. It features an oversized competition bolt knob, swept bolt handle, anti-bind design, AW/AICS magazine compatibility, nitride finish, and a smooth chrome-moly bolt with recessed lugs, Mini-16 extractor, and plunger ejector. Availability: Available through retailers including Red Hawk Rifles (add-to-cart with options) and Altus Shooting (currently out of stock for specific variants like RH/308) Cost: $1,495.00 Special: PRS-optimized with oversized bolt for fast cycling, AW magazine cut compatible with AW and AICS, integral rail/lug for rigidity, and included nitride finish at no extra cost 270 Videos Removed from YouTube for FRN and WLS in Recent Days 270 videos removed from youtube for FRN and WLS in the last several days. Supplementary Research: Firearms Radio Network (FRN) produces multiple gun-related podcasts including the long-running We Like Shooting (WLS) show, which features discussions on firearms, gear, training, and current events. The claim states that 270 videos associated with these channels were removed from YouTube over several days in 2026. YouTube's enforcement actions in 2026 have included widespread removals tied to updated policies on AI-generated content, community guidelines, and monetization standards, with millions of videos and channels affected platform-wide. Gun Fights Play the best Price Is Right-style GunBroker game on the internet. Gun Fights Live DisplayFollow the game, prices, and reveals as they happen.Open the live display BangRank A live cast ranking segment for anything and everything in the gun world, powered by questionable certainty, strong opinions, and audience voting. BangRank Live VotingScan or open the link to rank along with the show.https://welikeshooting.com/rank   WLS is Lifestyle GunCAD Index 2011 OPTICS MAXXING by Foaps Files Designed specifically for the Nightalliance 2011 Maxxing frames. There are two styles to choose from and six different optic mounting patterns. Each … This is a 3D model release on GunCAD Index containing STEP and STL files for optic mounts designed specifically for Nightalliance 2011 Maxxing frames. It offers two styles, six optic mounting patterns (including ACRO, Docter-Noblex, Pic Rail, RMR, RMSc, T1-T2), Gas Pedal and Non-Gas Pedal variants, plus length options for Full, Commander, and Short frames. The page serves as an indexed preview only; actual files must be acquired from the original source. Why it Matters: Enables precise red-dot integration on custom 2011 pistols in the growing 3D2A community, allowing shooters to upgrade iron-sight platforms with modern optics without factory limitations. The Vibe: Clean, modular CAD aesthetic with purposeful engineering details—gas pedal extensions, multi-pattern plates, and frame-specific lengths that emphasize performance-oriented customization over factory aesthetics. Hot Take: In the 2011 maxxing scene, bolting a quality optic directly to a printed or custom frame is now the baseline, not an afterthought. GunCAD Index Freedomware Sedco SP22:8 SPEDBRO SP22 Printable 22LR Pistol Don't like the standard Jennings J22? Well here's his neglected brother, the Sedco SP22. A knockoff of the already trash J22. NOT FOR DISTRIBUTION O… The SPEDBRO SP22 is a 3D-printable knockoff of the Sedco SP22 / Jennings J22 design by FreedomWare. It is a rimfire 22 Long Rifle handgun classified as a printed firearm using DIY barrel, bolt, and fire control with no firearm parts required. The release includes multiple STL files, reference images, a drill key, and README; total size 2.5 MiB; explicitly not for distribution on DEFCAD; tagged for FOSSCAD and 3D2A. Why it Matters: Provides a fully printable 22LR plinking handgun design that requires no commercial firearm parts, enabling DIY production of a simple rimfire pistol using consumer 3D printing and basic tools. The Vibe: Utilitarian homemade aesthetic with blocky printed polymer grips and frame, exposed metal DIY barrel/bolt, and reference photos showing side-by-side comparison to a Bryco 22; raw FOSSCAD open-source vibe with technical STL and drill-key files. Hot Take: A knockoff of the already trash J22 – the neglected brother Sedco SP22 now lives on as a fully printable FreedomWare project for the 3D2A community. Guncadindex Tritschi 60 Seconds Timer for Shooting Range A self-built horizontal hourglass-style mechanical countdown timer using a stepper motor, GT2 belt, Nema17, Arduino Nano, and 3D-printed parts. It provides a large 160 cm x 90 mm visual window that transitions from white to red over exactly 60 seconds for timing K20-K23 handgun events in DSU disciplines, with startup red LED/beeper sequence, green LED indicator, optional beeper, and planned light-sensor start. Powered by 3S Li-Ion with BMS; designed in TinkerCad and printed on Prusa MK4/Sovol SV08. Why it Matters: Best Use Case: Competition (K20-K23 handgun events in German DSU shooting sports; helps pace 18 shots in 60 seconds without digital distractions or crowd noise) Hot Take: Quick Pro/Con: Pro – Large peripheral-vision mechanical analog display improves focus and timing accuracy; Con – Self-built (requires 3D printing,...

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

Catching up with the Chat/Discord! The great Louisville debate! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

EXCLUSIVE: Trump Sparks 'Sitting Duck' Assassination Fears With Catering Cart 'Farce'Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Jason had a photo day and he's feeling good! Jason and Colleen share their nighttime skin care routines -- think face tape! JUST SAYIN': Colleen's plea to Costco -- people need shopping cart driver's ed! And we take a gander at Arby's new fall menu. UV umbrellas are trendy and will keep you safe from the sun! Bob Iger buys the Los Angeles Lakers and we speculate about what sports team we can buy (and afford...) and FIX MY LIFE: Lizzie's toilet troubles!SCREEN QUEENS: Holly stumbled into "Batman: Caped Crusader" on Amazon Prime, Jason is infuriated about "Double Lives of Suburban Wives" for a VERY specific reason, and Colleen completed her assignment by watching the first episode of "Dexter." Martha Stewart is gorgeous and serving looks! And remember that time that we almost got blown away at the Minnesota State Fair? Plus, Reader's Digest's list of things to do if you have a UFO sighting!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Join Valerie Abraham as she shares how her upbringing in France, life in America, and marriage to her Egyptian American husband have shaped her unique approach to cooking and hospitality. From Sunday morning coffee and pastries to practical table décor on a budget (including dollar store dishes!), Valerie offers inspiring ideas, kitchen must-haves she uses daily, three favorite book recommendations, and a flavorful menu influenced by multiple cultures. She also reminds us that hospitality is an imitation of God, the ultimate giver of every good gift. We close with a moving, thought-provoking conversation about both giving and receiving hospitality during a season of grief. We're so glad you're here! Visit www.comeoverfordinner.com for recipes, product links, and more!

In this week's episode, Blood editor Dr. James Griffin interviews Drs. George Goshua, Gerd Blobel, and Paul Kaminski on their latest articles published in Blood. Dr. Goshua elaborates on the background and then insights from "Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis". This analysis provides valuable guidance for clinicians, patients, and health systems as they consider treatment choices. However, as concluded in the accompanying Blood Commentary, the true measure of success is not which therapy “wins” the economic argument, but whether each patient receives the therapy best suited to their clinical needs and values. Then, Drs. Gerd Blobel and Paul Kaminski share "Dissecting polycomb complexes for enhanced fetal hemoglobin production", which utilizes a comprehensive CRISPR-based screen to interrogate the components of these repressive complexes and identified a single protein domain in EZH2, a subunit of PRC2, as a potential therapeutic target. They demonstrate that inhibition of the domain encoded by exon 14 of EZH2 selectively derepresses fetal hemoglobin expression, raising the possibility of developing drugs that specifically target this domain to treat hemoglobinopathies.

Wednesday, August 12, 2026 Today, Trump doesn't rule out using emergency executive power to interfere with the midterm elections; the transparency president has expanded the definition of executive privilege so his private advisors can't be questioned by Congress; the White House is asking the Justice Department to consider new Reflecting Pool charges; Trump was stuffed into a catering cart and spirited to a secret plane after he ditched the Qatari Air Force One in Turkey; weeks after Belgium's diamond industry gave Trump a ring with 321 diamonds, 56 sapphires, 13 emeralds and six rubies, it was exempted from paying a U.S. tariff; Judge Talwani has expanded her block on the Postal Service tampering with mail ballots; the government has awarded a $150M contract for migrant children's lawyers to a Trump-linked Texas law firm; plus Allison and Dana deliver your Good News. Thank You, HoneyLove Save 20% Off Honeylove by going to honeylove.com/DAILYBEANS #honeylovepod  #sponsored Thank You WildGrain Get $30 off your first box + free Croissants in every box. Go to Wildgrain.com/DAILYBEANS to start your subscription.  The Trump Epstein Memorial Bookmobile The Daily Beans is proud to partner with Miles Taylor and our friends at DEFIANCE.org For a limited time, members of the Daily Beans community can receive a FREE 3-month full membership to DEFIANCE.org and gain access to one of the fastest-growing pro-democracy movements in America. Join here: https://www.defiance.org/beans Diamond Dames - Subscribe here: https://youtube.com/playlist?list=PLdw5wpZniLeg&si=YB1KlvnjmA4CxxV3https://diamond-dames.simplecast.com/ The Latest Breakdown→ NEW: Judge Orders Todd Blanche to Explain Epstein Redactions in Open Court StoriesDemocrats want answers about 18-karat gold ring given to Trump | MS NOW Trump Said to Have Secretly Used Military Jet to Leave Turkey Amid Threats From Iran | The New York Times White House Asks Justice Department to Consider New Reflecting-Pool Prosecution | WSJ Trump executive privilege memo could hamper Democrats if they win Congress | CNN Politics Trump signals openness to unconstitutional plot to take over elections | Democracy Docket A judge expands a block on U.S. Postal Service work on Trump's mail-in voting order | NPR Trump administration awards $150M migrant child contract to Texas firm | AP News Good Trouble Friday August 28 in DCMarch On Washington 2026 -marchonwashington2026.com March on Washington: Defend the Vote - Mobilize Check your voter registration and deadlines → Voter Registration Deadlines - Vote.org →Blue Wave California- secure.actblue.com/donate/msw-bwc →Helpline Orientation- Spanish Speakers Needed! · VoteRiders →Help save Texas from Ken Paxton! →NO HATE in WA State →Stand With Minnesota →iceout.org Good Newsdana-goldbergs-southwest-funnyfest Oct 9 -Email Dana@DanaGoldberg.com for sponsorship informationTickets for Dana Goldberg: Outrageous - Sep 23 - Den Theater - Chicago  →Share your Good News & Good Trouble - The Daily Beans →Beans Talk audio -beans-talk.simplecast.com Subscribe to the MSW on YouTube - MSW Media - YouTube Our Donation Links The Trevor Project - trevorproject.org/beans Blue Wave California - ActBlue.com/donate/msw-bwc Donate to Public Citizen - https://citizen.org/beans/ Donate to It Gets Better / The Daily Beans Fundraiser Pathways to Citizenship - boomerang - pathways  Dana and The Daily Beans support of Human Rights Campaign ONE CAUSE HRC The Daily Beans supports It Gets BetterNational Security Counselors - Donate, WhistleblowerAid.org/beans Dr. Allison Gill - The Breakdown | Allison Gill, Mueller, She Wrote @muellershewrote.com - Bluesky, MSW & The Daily Beans Podcast @muellershewrote - Instagram, MSW Media - YouTube →Federal workers email AG - fedoath@pm.me Dana Goldberg - Dana is on Patreon! At Dana's Dugout, @dgcomedy - Bluesky, @dgcomedy - IG, Dana Goldberg - Facebook,  DanaGoldberg.com More from MSW Media - Shows, Cleanup On Aisle 45 pod, The Breakdown | Allison Gill Reminder - you can see the pod pics if you become a Patron. The good news pics are at the bottom of the show notes of each Patreon episode! That's just one of the perks of subscribing! patreon.com/muellershewrote Listener Survey:http://survey.podtrac.com/start-survey.aspx?pubid=BffJOlI7qQcF&ver=shortFollow the Podcast on Apple:https://apple.co/3XNx7ckWant to support the show and get it ad-free and early?https://patreon.com/thedailybeanshttps://dailybeans.supercast.com/https://apple.co/3UKzKt0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Double Tap Double Tap - Ep 474 August 10, 2026 Presented by This episode of Double Tap is brought to you by: Foxtrot Mike (Code: WLSISLIFE) C&G Holsters (Code: WLSISLIFE) Gideon Optics (Code: WLSISLIFE) Midwest Industries (Code: WLSISLIFE) Blue Alpha Giveaways!! GAW   Text Dear WLS or Reviews +1 743 500 2171 Public   Show Titles   Dear WLS Question from Ben B from Kansas Ben B (TLDR from last week: Bought a Bergara B14-HMR that wouldn't group and had a crooked-looking scope. After replacing the rail, rings, and checking the scope, a gunsmith finally discovered the rifle's mounting holes were drilled at a 45° angle from the factory. The manufacturing defect that made proper alignment impossible.)Continuation of the story from where it cut off last week- We looked in there and about half the threaded hole in the receiver was visible through the rail. Well shit… We tried a different rail and it was the same. I decided to contact Bergara to see if they would fix it. I started a warranty case with them and they sent an RMA form and asked me to ship the rifle to them. I sent it over and assumed that everything would be straightened out. After several weeks with zero updates, I called and asked for some kind of information. I even gave them exact instructions on how to replicate the problem. They said they would update me when they got it into their system and when they got started on the inspections. After they had it for a month they finally shipped it back and their conclusion was that the rifle was in spec. About a million emails later and both sides being stubborn, I gave up. Obviously they weren't going to fix it and I was at my wit's end. I brought it back to the gunsmith and had him drill and re tap the receiver holes to a big enough size to line it up. In spec my ass. Ever since then the Bergara name has left a bad taste in my mouth. I'm not really on social media and don't know how to get through how bad of an experience I had with them because I think people need to know. I am sorry for the long story but I already left a lot of details out. Just remember you asked for this Shawn Question from Bama Chris I know this will take forever And I'm expecting And answer sometime in about 2029 … Just found out the other day from Savage that my current credit card provider that used to be discover card and is now Capital One is a bunch of anti-gun Cucks … I need to cancel My over 20-year account With this credit card company Actually I have two accounts Cancel them both And find a credit card company That is 2a friendly Any suggestions… This is for Customer-Based Credit line Not Business related Processing. Wouldn't man if it was A car that instead of me getting cash back All of that went towards donations Second Amendment Foundation or other Friendly OrganizationsThanks Five squares second call defense is awesome High Point rules and Jeremy is my spirit animal Question from Anonymous Coward from Kentucky Question from Coward with anonymity from Virginia. I know you have probably said it a hundred times, but I have no experience with 3d printing. What is the best starter printer that's user friendly and capable. Great show, thanks! Question from Peter J from WA Peter J from WA, Dear WLS, I'm interested in either buying a factory ported pistol or having one I own custom ported. Is it really worth the hype? Im debating on either getting a CZ ported P10c or getting my CZ P10F ported. Use case would be more for range but would carry the ported p10c since I carry a non ported one currently. I more than with do what Jeremy or Nick tell me what to do. Thanks Question from eTexNerd from Texas Dear wls, from eTexNerdFirst a big Ole howdy from the upper east side of Texas to Tom Bowers! Question: once Bowers group is running production in Texas, won't I be able to buy his suppressors without federal redtape? I think Texas passed a law to allow intrastate transfer of suppressots made within Texas. I'm a little vague on the legal details but figure Tom being in the industry would know more. Maybe the cartoon savage legal hawk can explain this too. VIVA LA TEJAS! WINNER Question from Anonymous Coward from Texas Dear WLS. from Organiv Nut Milk Producer,Last week I learned about a new trend called ballmaxxing. Assuming one wished to take up this hobby, would you recommend switching from appendix carry to SOB? Gun Industry News Inside Safariland Derya Arms Derya MAX Cadre Derya Arms (Jacksonville, FL) has released the Derya MAX, a proprietary magazine-fed 12-gauge semiautomatic shotgun developed over three years with input from champion-level competitive shooters. It uses a self-cleaning curved gas piston that reliably cycles loads from 7/8 oz target shells to 3″ magnums, incorporates a proprietary MAX Brake and double-buffered recoil system to minimize muzzle rise and felt recoil, and ships with a hard case, tool roll, and magazines. The design targets 3-Gun, IPSC, home defense, and training applications with an adjustable adaptive stock, AR-compatible pistol grip, full-length Picatinny rail, flip-up iron sights, and threaded barrel. The Gist: Recently released (no specific date or retailers stated) Impact: $2,499.00 MSRP Bottom Line: 12 ga; 5/10-round magazine capacity; self-cleaning gas piston; 14″, 18″, or 20″ barrel options; 38″ OAL, 9.5 lb; folding iron sights, full Picatinny rail, mobile chokes (Full/Modified/IC), adjustable stock (12-15″ LOP), MAX Brake + double-buffered recoil system, ships with 2 magazines (6 + D-TAK optic in Factory Exclusive version) Theoutdoorwire SK Guns Relaunches Limited Edition Pancho Villa from La Revolucion Series in Stainless Steel SK Guns has relaunched the first pistol in its La Revolucion series as a limited-edition stainless steel Full Size Government Model Colt 1911 chambered in .38 Super. The highly polished revolver-style 1911 features selective 24k gold plating, intricate historical engravings commemorating Pancho Villa and the Mexican Revolution, and custom Antique Pearl Krinite grips with antique gold peso coin medallions. Limited to 300 units, it marks the 100th anniversary of Pancho Villa's passing (1878-1923). The Gist: Relaunched August 7, 2026; limited to 300 units; follow SK Guns on Instagram and Facebook for production launches Bottom Line: Caliber .38 Super; stainless steel frame, slide, barrel and hardware with selective 24k gold plating; engravings include Monument to the Revolution, “División del Norte” banner “Fusílenlo, después averiguamos”, Durango coat of arms, “REVOLUCION”, “El Centauro del Norte”, Pancho Villa portrait “1878-1923 Centenario”, bandolier with .30-30 cartridges, Mexico coat of arms 1899-1947, and Cannas floral scroll with selective shading; Antique Pearl Krinite grips with replica antique gold peso medallions Eaacorp Girsan Witness2311 CMXX The Girsan Witness2311 CMXX from EAA Corp. is a compensated single-action 2011-style pistol offered in 9mm, 10mm, and .45 ACP. It features an integral barrel compensator, 4.25″ bull barrel, lightening-cut slide, RMSc optic-ready footprint, tuned 4.5 lb trigger, auto firing pin block safety (no grip safety), ambidextrous thumb safety, full accessory rail, and improved high-texture grips with a Cerakote black finish. The Gist: Available for purchase now (listed as NEW on EAA Corp. website) Impact: Starting at $1,149 (MSRP) Bottom Line: 9mm (17+1), 10mm (15+1), or .45 ACP (11+1); 4.25″ bull barrel with integral compensator; RMSc optic ready, fiber optic front sight, tuned 4.5 lb trigger, auto firing pin block, ambidextrous thumb safety, full accessory rail, Cerakote black finish, EAA limited lifetime warranty Walkersgameear Walker's Game Ear Boomies Passive Muffs Walker's Game Ear Boomies Passive Muffs are a toddler-specific (ages 1–3) passive hearing protection product with a certified NRR of 23 dB. The slim, lightweight design features soft ear cushions, impact-resistant materials, and a contoured, stay-put fit engineered for active play and small head sizes without requiring batteries or electronic components. The Gist: Currently available for purchase (listed as new product with Add to Cart option) Impact: $29.99 MSRP Bottom Line: Passive NRR 23 dB; lightweight/contoured for toddlers 1–3 years; soft cushions, impact-resistant, stay-put fit for active indoor/outdoor use; no batteries or switches; SKU GWP-YM2-VAR Before we let you go – Join Gun Owners of America We'd love if you supported the show, join Agency 171 at agency171.com. Lot's of prizes, rewards and kick ass swag. No matter how tough your battle is today, we want you here fight with us tomorrow. Don't struggle in silence, you can contact the suicide prevention line by dialing 988 from your phone. Remember – Always prefer Dangerous Freedom over peaceful slavery. We'll see you next time! Nick – @busbuiltsystems | Bus Built Systems Jeremy – @ret_actual | Rivers Edge Tactical Aaron – @machinegun_moses Savage – @savage1r Shawn – @dangerousfreedomyt | @camorado.cam | Camorado

Guest: Dr. Pere Santamaria is a Professor at the Cumming School of Medicine at the University of Calgary and Group Leader at the Barcelona Institute. He discusses how his lab studies the mechanisms underlying autoimmune diseases, with a focus on regulatory T cell biology and antigen-specific immune tolerance. He also explains how his team developed a nanomedicine platform that reprograms autoreactive T cells into regulatory cells, offering a targeted approach to treating autoimmune disorders without suppressing normal immune function, and shares the challenges of translating this technology from the lab to the clinic. Featured Products and Resources: Find the right antibodies for your research and start integrating them into your workflow. Get a free copy of a Nature Protocols wallchart outlining the production of therapeutic CAR T cells. The Immunology Science Round Up Maternal Vaccine Against GBS – A Phase I/II trial shows that a maternal hexavalent Group B Streptococcus vaccine is safe and elicits robust antibody responses in both mothers and infants. Decoding Treg Differentiation – TCR specificity and antigen presentation context determine regulatory T cell differentiation and phenotype, providing a framework for antigen-specific immune tolerance. A Microbiota–Autoimmunity Axis – Disrupted dendritic cell development promotes gut dysbiosis that drives inflammatory dendritic cell expansion and systemic autoimmunity. Programming Regulatory T Cells – Arginine availability regulates MHC class I antigen presentation, influencing antiviral immunity and cancer development. Image courtesy of Dr. Pere Santamaria. Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy's (ASTCT) program ASTCT Talks, Terri Lynn Shigle, PharmD, BCOP hosted Vinita Pai, PharmD, MS, BCPPS, who spoke about the use of CAR T-cell therapy for pediatric patients, focusing on acute lymphoblastic leukemia (ALL).After a brief overview of progress in the cellular therapy field and pediatrics' first and only FDA approved CAR T product since 2017, their discussion explored the following:Review of real-world practice and outcomes in ALLPediatric practical challenges including logistics, leukapheresis, and lymphodepletion chemotherapyStrategies for managing cell therapy toxicities in pediatricpatientsConsiderations for survivorship and long-term toxicitiesGaps in pediatric care and future directionsListen below or via your favorite podcast platform.ReferenceO'Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142-1146. doi:10.1158/1078-0432.CCR-18-2035

Lupus is a condition dermatologists know as one of the great diagnostic mimics. In this episode, Dr Jacqueline Jiang and Associate Professor Alvin Chong sit down with rheumatologist Professor Alberta Hoi and dermatologist Associate Professor Laura Scardamaglia to demystify this complex autoimmune condition. We dive into the different classifications, how lupus presents and how it’s diagnosed. We also discuss where treatment is heading, from sun protection and hydroxychloroquine through to newer therapies such as anifrolumab and breakthroughs in CAR-T cell therapy.See omnystudio.com/listener for privacy information.

*نخستین قسمت از سری برنامه‌های «نبض علم» (Science Pulse)*در جهان امروز که روزانه صدها مقاله و خبر علمی در معتبرترین مجلات و ژورنال‌های پژوهشی دنیا منتشر می‌شود، تشخیص یافته‌های واقعاً تحول‌آفرین از بزرگ‌نمایی‌های رسانه‌ای چالش بزرگی است. برنامه «نبض علم» (Science Pulse) در پادکست هوشیار با همین هدف شکل گرفته است تا مهم‌ترین اخبار و کشفیات علمی ماه از منابع معتبری چون Nature، Science، Cell، Scientific American و New Scientist را به زبانی ساده، دقیق و مبتنی بر شواهد تحلیل و بررسی کند.*میزبانان و گفتگوکنندگان:دکتر مهدی شفا (زیست شناس سلولی و‌مولکولی، پژوهشگر حوزه سلول و‌ ژن درمانی)فرهاد ارکانی (نویسنده، پژوهشگر مستقل و سازنده پادکست علمی-فلسفی بنفش و خوانش کتاب برای انسان خردمند)در این گفتگو مهم‌ترین موضوعات علمی اخیر از جمله دستاوردهای #هوش_مصنوعی در پژوهش‌ها، تحولات #پزشکی و ژنتیک، مرزهای #فرگشت انسان، کشفیات تازه در #نجوم و مسئله سه جسم، و آخرین یافته‌ها درباره منشأ حیات در #کیهان به تفصيل نقد و بررسی شده‌اند.*کتاب‌های معرفی و بررسی‌شده در این گفتگو:*در طول برنامه به چند اثر شاخص علمی و فلسفی جهان اشاره شد که اسم انگلیسی و ترجمه فارسی آن‌ها به شرح زیر است:1. *Nexus: A Brief History of Information Networks from the Stone Age to AI* نوشته یووال نوآ هراری | ترجمه فارسی: «نکسوس: تاریخ مختصری از شبکه‌های اطلاعاتی از عصر سنگ تا هوش مصنوعی»2. *Why We Die: The New Science of Aging and the Quest for Immortality* نوشته ونکی راماکریشنان | ترجمه فارسی: «چرا می‌میریم: علم جدید پیری و تلاش برای جاودانگی»3. *Lifespan: Why We Age—and Why We Don't Have To* نوشته دیوید سینکلر | ترجمه فارسی: «طول عمر: چرا پیر می‌شویم و چرا مجبور نیستیم»4. *Astrophysics for People in a Hurry* نوشته نیل دگراس تایسون | ترجمه فارسی: «اخترفیزیک برای افراد بی‌قرار» (یا اخترفیزیک برای انسان‌های شتاب‌زده)5. *The Three-Body Problem* نوشته سلیو شین (لیو سیشین) | ترجمه فارسی: «مسئله سه جسم»*زمان‌بندی موضوعات گفتگو (Timestamps):*00:00:00 مقدمه و معرفی: سری جدید برنامه‌های «نبض علم»00:03:34 هوش مصنوعی در پژوهش: دستیار هوشمند و انقلاب در فرضیه‌سازی00:11:48 کشف آنتی‌بیوتیک‌های جدید: شتاب‌دهی هوش مصنوعی و حل بحران مقاومت دارویی00:17:48 تحول در سرطان‌درمانی: فناوری سلول‌های CAR-T و هدف‌گیری تومورهای جامد00:23:00 صنعت داروسازی و چالش‌ها: نقد تئوری‌های توطئه و مافیای دارو00:28:39 داروهای چندمنظوره GLP-1: کاهش خطر آلزایمر و پیشگیری از سرطان00:38:06 ویرایش دقیق ژنوم: تکنولوژی Base Editing و درمان بیماری‌های ژنتیکی00:44:05 فرگشت و دی‌ان‌ای باستانی: آمیزش‌های مکرر انسان هوشمند و نئاندرتال‌ها00:50:43 ردپای ژنتیکی هومو ارکتوس: بازنگری در درخت فرگشتی انسان00:53:18 شیمی منشاء حیات: نقش فسفات‌ها و کشف قندهای کیهانی00:56:44 زیست‌شناسی مصنوعی: ساخت اولین سلول مصنوعی با قابلیت تکثیر00:58:06 فیزیک و اخترشناختی: کشف منظومه سه‌تایی و مسئله سه جسم01:09:44 ترویج و همگانی‌سازی علم: گفتگو با نیل دگراس تایسون و جایزه پرایز01:15:50 جمع‌بندی و سخن پایانی: تشویق کنجکاوی و تفکر شواهد‌محور───────────────────────────اگر به درک عمیق‌تر جهان هستی، تفکر انتقادی، شناخت مرزهای آگاهی و آگاهی از تازه‌ترین یافته‌های علمی جهان علاقه‌مند هستید، عضویت در این کانال گامی در مسیر کنجکاوی خردورزانه خواهد بود. با سابسکرایب کردن کانال و فعال‌سازی زنگوله، در این گفتگوی جهانی علم همراه ما باشید.— — — — —*

In a cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy's (ASTCT) program ASTCT Talks, Terri Lynn Shigle, PharmD, BCOP, hosted Vinita Pai, PharmD, MS, BCPPS, who spoke about the use of CAR T-cell therapy for pediatric patients, focusing on acute lymphoblastic leukemia (ALL). After a brief overview of progress in the cellular therapy field and pediatrics' first and only FDA-approved CAR-T product since 2017, their discussion explored the following:·      Review of real-world practice and outcomes in ALL·      Pediatric practical challenges including logistics, leukapheresis and lymphodepletion chemotherapy·      Strategies for managing cell therapy toxicities in pediatric patients·      Considerations for survivorship and long-term toxicities·      Gaps in pediatric care and future directionsThe discussion highlighted the unique challenges of treating pediatric patients, paucity of data, and need for continued exploration of cellular therapy treatment not only in ALL, but other underlying diagnoses. Shigle is a clinical pharmacy specialist in the Stem Cell Transplantation & Cellular Therapy Department at The University of Texas MD Anderson Cancer Center. Pai is an associate clinical professor in the Division of Pharmacy Practice and Science at The Ohio State University.ReferenceO'Leary MC, Lu X, Huang Y, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142-1146. doi:10.1158/1078-0432.CCR-18-2035

The Tim Corrimal Show Episode 844 – August 9, 2026 On episode 844 of The Tim Corrimal Show, I am joined at the round table with Joe (Joseph Santorsa on Facebook and @marnus3.bsky.social on BlueSky) and Cathy (@cathylarkin.bsky.social on BlueSky) and from the Let's Remember To Never Forget Facebook Page. On the show this week we […] The post Episode 844 – I Don't Want to go on the Cart first appeared on The Tim Corrimal Show.

Why is gene therapy still so difficult to manufacture at scale after decades of progress?Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversation about one of the central challenges facing advanced therapies: turning extraordinary science into reproducible, scalable medicines.Thank You to Our SponsorsLeucentra - https://leucentra.com/Inspired by Science. Empowered by IT. Leucentra provides specialized IT consulting and services for life sciences and healthcare, helping organizations use technology more effectively to support innovation.TruTechnologies - https://trutechnologies.ai/Clinical Trial Execution, Live. TruTechnologies provides live clinical trial execution technology that gives sponsors greater visibility into protocol activities, samples, and study data as they happen.About This EpisodeRecorded onsite at the AAPS National Biotechnology Conference in Boston, Phillip explains why gene therapy manufacturing has not yet reached the maturity of monoclonal antibody production.As technologies have evolved across retroviral vectors, lentiviral vectors, adenovirus, AAV, lipid nanoparticles, and other advanced modalities, development teams have repeatedly been required to rethink fundamental manufacturing and analytical questions.Phillip discusses why analytics are critical, why experience across multiple manufacturing lots and products matters, and why there simply is no shortcut to developing the scientific knowledge necessary to manufacture advanced therapies reliably.He also reflects on the uncertainty of biotechnology.Early in his career, Phillip was walking down a hallway when his CFO asked if he had cashed his paycheck.When he said no, she told him not to.It's a remarkable story that captures something rarely discussed about biotechnology: behind transformative science are people willing to operate through considerable uncertainty while trying to build something that has never existed before.Gregory and Phillip Discuss• Viral vector manufacturing and scale-up• Why analytics are essential to gene therapy development• AAV manufacturing challenges• Lentiviral vectors and other evolving delivery technologies• Lipid nanoparticles and changes in advanced therapy manufacturing• Why gene therapy cannot simply adopt the established monoclonal antibody manufacturing playbook• Building process knowledge across lots and products• Career resilience in biotechnology• Progress across AAV, CAR-T, and other advanced therapies• Gene therapy affordability• The importance of therapeutic durability• Outcomes-based payment models for advanced therapiesPhillip's message for scientists and industry leaders is straightforward: don't assume the manufacturing problem has already been solved simply because a technology has existed for decades.The field is still evolving, and some knowledge cannot be shortcut.About Phillip RamseyPhillip Ramsey is Chief Technical Officer at Sangamo Therapeutics and brings more than 35 years of experience across biotechnology and pharmaceutical manufacturing, technical development, operations, quality, and advanced therapies.Connect with Phillip Ramsey:https://www.linkedin.com/in/phillip-ramsey-a2074711/Sangamo Therapeutics:https://www.sangamo.com/Connect With BioTalk UnzippedGregory Austin on LinkedIn:https://www.linkedin.com/in/gregoryaustin1/Dr. Chad Briscoe on LinkedIn:https://www.linkedin.com/in/chadbriscoe/BioTalk Unzipped:https://www.biotalkunzipped.com/BioTalk Unzipped unzips, unlocks, and uncovers the stories behind medical progress through conversations with scientists, executives, entrepreneurs, and innovators advancing biotechnology, pharmaceuticals, and medical technology.Recorded onsite at the AAPS National Biotechnology Conference in Boston.Special thanks to AAPS and Rebecca Stauffer for supporting the BioTalk Unzipped interview series.

Medical breakthroughs rarely happen overnight. They begin with an idea, grow through years of research, and eventually reach the patients whose lives they may change. Andrea Lopez has spent her career helping make that journey possible. In this week's Celebrate Your Story, Andrea shares how a childhood fascination with medicine led her from Ecuador to New York, where a professor's encouragement opened the door to a career in cancer research. Today, she works at the forefront of CAR T-cell therapy, helping hospitals deliver treatments that harness a patient's immune system to fight cancer. Our conversation explores what it takes to turn a scientific discovery into a life-changing therapy and how AI is giving researchers new tools to understand complex data. Andrea also reflects on the mentors who shaped her career and explains why she believes the best leaders recognize potential in others before those individuals recognize it themselves. If you've ever wondered what happens between a breakthrough in the laboratory and a treatment in the hospital, you'll come away from this episode with a deeper appreciation for the people whose work is quietly reshaping the future of medicine.  

Catching up with the Discord! NBA equivalents for our favorite college basketball teams! Superlatives using Jeff Borzello's top 25! The Sleepers Podcast is now available daily with new episodes every Monday-Friday! The College Basketball stock market is LIVE on Stakeholder! Buy low or sell high on teams as they lose and add players in the portal! Join using our link for an instant $15 bonus: https://stak3holder.com/join/sleepersmedia Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Drs. Matthew Frank and Jieqing Zhu on their latest articles published in volume 147 issue 22 of Blood. Dr. Frank discusses "How I treat HLH-like toxicities after immune effector cell therapy", in which the two cases presented emphasize the need for early identification, the use of anticytokine therapy with either emapalumab or ruxolitinib when organ toxicities worsen despite conventional CRS-directed treatment, and the need for ancillary supportive care as central to success. Dr. Zhu shares insights from "Structural Basis of HPA-1 a Alloimmunization in FNAIT and Allosteric Regulation of Integrin Conformation" where they probed the structure-function relationships underpinning interactions of alloantibodies against the most common target, human platelet antigen 1a (HPA-1a). Their data can help explain why some alloantibodies cause severe hemorrhagic FNAIT while others result in milder, asymptomatic thrombocytopenia.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the intricate web of scientific advancements, regulatory updates, and strategic maneuvers shaping the industry. Let's begin with Eli Lilly's impressive financial performance, clocking a record-breaking $23 billion in revenue for Q2 2023. This achievement, driven by the success of Mounjaro and Zepbound in metabolic diseases, underscores the competitive landscape of therapies targeting chronic conditions. However, the slower launch of Foundayo highlights ongoing challenges. Meanwhile, competition in obesity treatments is intensifying as Novo Nordisk's Wegovy continues to dominate despite new entrants like Eli Lilly's Foundayo. This scenario reflects growing patient preference for oral medications over injectables. Gilead Sciences' HIV prevention franchise has exceeded $1 billion in quarterly sales, reflecting an increasing reliance on effective small molecule therapies for infectious diseases. Gilead also remains a focal point with its HIV pre-exposure prophylaxis franchise reaching sales milestones amid legal victories defending their tenofovir-based treatments. These legal precedents could influence future innovation policies across the industry. Artificial intelligence continues to make waves in drug discovery and clinical trials. Icon's partnership with Anthropic aims to integrate AI capabilities to accelerate drug development timelines. Similarly, Phylo and Chugai Pharmaceutical are collaborating to optimize drug discovery workflows using advanced AI platforms. These collaborations highlight a strategic move towards enhancing efficiency in drug development processes. In oncology, Amplia Therapeutics and Eli Lilly are evaluating a combination therapy for non-small cell lung cancer, while Evexta Bio and Roche are exploring a joint study for metastatic breast cancer. These partnerships underscore the industry's focus on combination therapies and precision medicine to improve cancer treatment outcomes. Additionally, AstraZeneca's partnership with CSPC Pharmaceutical to enhance biologics manufacturing in China signifies the importance of localized production capabilities. On the regulatory front, Arrowhead Pharmaceuticals' acquisition of an FDA rare pediatric disease priority review voucher for Plozasiran represents a commitment to addressing unmet needs in rare diseases. This voucher could expedite new drug applications, potentially bringing life-saving treatments to patients more quickly. Despite these advancements, challenges persist. Novo Nordisk's Cagrisema failed to achieve its primary endpoint in a Phase 3 trial for type 2 diabetes, highlighting the complexities of developing combination therapies for metabolic disorders. Similarly, Eli Lilly's discontinuation of its Phase 1/2 trial for GBA1 gene therapy reflects the hurdles faced in advancing gene therapies. Looking at industry dynamics, Amgen's decision to discontinue its early-stage obesity drug signifies a strategic shift towards focusing on more promising pipeline candidates like Maritide. This move aligns with broader trends prioritizing candidates with significant potential impact on patient care. Amgen's 'Repatha' is experiencing renewed interest due to positive cardiovascular risk reduction data, showcasing how robust clinical results can rejuvenate existing products. In regulatory news, Merck's 'Lipfendra' has been spotlighted by the FDA as part of its Complex New Product Validation pilot program. This positions Lipfendra as a potential game-changer in the PCSK9 inhibitor category. Lastly, financial maneuvers such as Attovia Therapeutics' $289 million IPO and Expedition Therapeutics' $115 million Series B funding highlight investor confidence in novel therapeutic areas like dermatological and respiratory treatments. The pharmaceutical landscape remains dynamic with Johnson & Johnson investing heavily in gene therapy ventures like Sail Biomedicines for CAR-T therapies. Meanwhile, regulatory challenges persist as seen with Capricor's cell therapy setback due to statistical complexities during FDA reviews. Despite setbacks faced by some companies, innovations continue to thrive. The launch of personalized genetic therapy centers signals a shift towards individualized medicine while research into safer CAR-T therapies progresses. In conclusion, these developments reflect an industry driven by innovation amidst regulatory challenges and strategic adjustments. As companies navigate this evolving landscape, their decisions will shape future healthcare innovations and patient care outcomes. Thank you for joining us on Pharma Daily; stay tuned for more insights from the world of pharmaceuticals and biotech.Support the show

Dr. Olga Klinkova, Infectious Diseases Physician at the Moffitt Cancer Center and Research Institute, presents an introductory session on the management of the immunocompromised patient. Dr. Klinkova begins by explaining the major immune deficits in patients with hematologic malignancy and stem cell transplantation (SCT). She then outlines the likely pathogens that produce infections based on the timeline after cancer therapy or SCT. She further explains the major pulmonary syndromes seen in hematologic malignancies and transplant. Lastly, she discusses infections that can occur after CAR-T therapies as well as CMV infection post-transplant.

Don't have time to listen to the entire Dave & Chuck the Freak podcast? Check out some of the tastiest bits of the day, including chuck's new album songs of Cart-Man, a fart forces people to leave the new Spiderman movie and so much more!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of late relapse refractory multiple myeloma treatment. Joined by Maximilian Merz, MD, a myeloma specialist from the Memorial Sloan Kettering Cancer Center, the discussion covered the evolving treatment landscape, including the use of CAR-T cell therapies, bispecific antibodies, and the importance of assessing BCMA expression. Key topics included: The current treatment algorithms for late relapse refractory multiple myeloma The significance of antigen expression in guiding treatment decisions The role of bispecific antibodies like teclistamab and talquetamab Managing side effects and improving patient quality of life The importance of collaboration between community hematologists and tertiary care centers Join us as we explored the latest advancements in myeloma treatment and the critical role of patient education and support in navigating this challenging disease. Don't forget to check out our previous episodes on newly diagnosed multiple myeloma and early relapse refractory disease!   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/  Subscribe for more insights and updates on oncology treatments! #MultipleMyeloma, #CART, #BispecificAntibody, #RelapsedMyeloma, #OncologyBrothers

The "Community Meets Clinic" podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode, Krissy Dilger of SRNA spoke with Dr. Elena Grebenciucova, an assistant professor of neurology and neurological infections at Northwestern University in Chicago, Illinois, leading its Transverse Myelitis Center, a designated Center of Excellence in Rare Neuroimmune Disorders. She described Northwestern's multidisciplinary clinic for transverse myelitis, NMOSD, MOGAD, neurosarcoidosis, and related autoimmune conditions, including collaboration with Shirley Ryan AbilityLab and specialists such as pain management, neuro-urology, rehabilitation, and neurosurgery, with an emphasis on faster access to care [04:08]. Dr. Grebenciucova outlined research and clinical trial efforts, including studies on transverse myelitis natural history, optic neuritis therapies, plasma exchange timing, and CAR T-cell strategies [08:36]. View the medical profile of Dr. Grebenciucova:https://www.nm.org/doctors/1467708305/elena-grebenciucova-mdElena Grebenciucova, MD completed neurology residency at the University of Chicago in Chicago, Illinois. Dr. Grebenciucova has been interested in autoimmune disorders of the central nervous system, including rare neuroimmune disorders, since medical school. After residency, she completed a neuroimmunology Fellowship under the mentorship of Dr. Brenda Banwell and Joseph Berger at the Perelman School of Medicine of The University of Pennsylvania. Currently she is an assistant professor of Neurology (MS/Neuroimmunology) and neurological infections at Northwestern University in Chicago, Illinois, and she runs the Transverse Myelitis Center there. Dr. Grebenciucova sees patients with rare autoimmune conditions including NMOSD, MOGAD, transverse myelitis, and autoimmune encephalitis.00:00 Series Introduction00:52 Meet Dr. Elena Grebenciucova01:38 Her Path to Neuroimmunology04:08 Northwestern TM Clinic Overview08:36 Research and Clinical Trials11:16 How to Access the Clinic12:46 Multidisciplinary Care Team15:32 Self Care and Lifestyle18:55 Why Choose Northwestern21:45 Hope for the Future23:17 Closing

Cinco días antes de Navidad de 1984, Jonelle Matthews, de 12 años, desapareció de su casa en Greeley, Colorado. Su rostro fue de los primeros en aparecer en los cartones de leche, pero aquella difusión no consiguió traerla de vuelta.

>p>Broadcast from KSQD, Santa Cruz on 7-30-2026: A type of coffee brewed from beans that have been altered by passage through the digestive track of civet cats is a delicacy in Southeast Asia. A Scientific Reports paper using gas chromatography analyzed Kopi Luwak (civet-processed coffee beans) versus fresh-picked beans, finding elevated caprylic and capric acids that carry the characteristic flavor notes found in dairy products. Dr. Manuel Esteller sampled and tested the blood, saliva, urine, and stool of the oldest human Maria Branyas Morera, who died last year at 117. Despite exceptionally short telomeres, she carried anti-inflammatory genetic variants seen in long-lived dogs, worms, and flies, and had unusually high Bifidobacterium levels—likely boosted by her three-daily-servings-of-yogurt habit. Dr. Dawn defends sunscreen use against Environmental Working Group scare campaigns, noting that concerns about absorption of sunscreen ingredients into blood remain theoretical while sunburn's melanoma link is well-established. She argues that a badly sunburned toddler starts a clock that can produce melanoma by the late teens. The FDA advisory committee is reviewing certain short amino acid chains popularly known as "peptides" for potential compounding-pharmacy production, covering proposed to treat ulcerative colitis, wound healing, insomnia, insulin resistance, migraines, and osteoporosis. Dr. Dawn flags that five to seven committee members have industry conflicts of interest, but argues that even flawed approval is preferable to the current gray market, where analysis shows vials contain only 4-28% of labeled content along with endotoxin and toluene contamination. She proposes surveillance tracking of prescribed peptides to catch adverse effects early, citing a foreign melanocortin nasal spray tanning product that caused rare nasal melanomas as a cautionary example. Utah State biochemists working with the Cas12a2 CRISPR enzyme discovered that instead of behaving as a precise gene-editor like Cas9, it goes into an indiscriminate DNA-shredding mode after recognizing its target RNA. By programming it to recognize RNA sequences uniquely activated in cancer cells (embryonic-development genes that shouldn't be running in adults), researchers destroyed only the cancer cells in tissue culture, potentially offering a way to eliminate small metastases without healthy tissue toxicity. Cancer patients who received a COVID-19 mRNA vaccine within 100 days of starting immune checkpoint inhibitor therapy showed dramatically improved outcomes, with median survival in advanced lung cancer rising from 20 to 37 months. Non-mRNA vaccines (flu, pneumonia) showed no such benefit. Lab work suggests the mRNA triggers type-1 interferon release that activates tumor-infiltrating immune cells and drives them to lymph nodes to train other immune cells against the tumor. Researchers redesigned a CD40 agonist antibody to bind multiple receptors simultaneously by clustering with a second antibody, stretching the cell surface and triggering a powerful immune response. In a 12-patient trial, injecting one tumor caused all tumors to shrink in six patients and produced complete remission in two—including a melanoma patient with dozens of leg tumors and a metastatic breast cancer patient whose lung and liver tumors resolved after skin injection. Two small trials of CAR natural killer cells—engineered like CAR T-cells but derived from donor umbilical cord blood and thus potentially available off-the-shelf—showed remarkable results in autoimmune disease. All 27 systemic lupus patients targeting the CD19 protein on autoantibody-producing cells showed improvement, with some remaining in remission at nearly two years. A single Shanghai patient with systemic sclerosis showed restoration of normal skin and blood vessel structure. A paradox has emerged in advanced prostate cancer: while blocking testosterone halts early tumor growth, cancer cells eventually adapt to low-androgen conditions such that flooding tissues with testosterone in advanced disease can actually halt tumor progression by triggering cellular redifferentiation. Separately, Dr. Dawn reviews conflicting evidence on Parkinson's risk from androgen deprivation therapy, singling out enzalutamide (Xtandi) as the most concerning drug due to blood-brain barrier penetration, and recommending darolutamide as the safest alternative with matching prostate efficacy but minimal CNS entry.

Welcome back to Not A Bomb, the podcast where we resurrect cinema's most infamous box office disasters and ask the burning question: is it a bomb? This week, Troy and Brad strap into the chaotic, nitro‑fueled world of the 2001 racing epic Driven. And before we go any further, yes, Troy is back from surgery and only slightly a little high on pain medication, which honestly might be the perfect state of mind for revisiting a movie this unintentionally wild.Driven arrived during the era when Hollywood believed the cure for every script problem was “more CGI, more speed, more Stallone.” The film promised high‑octane racing, intense rivalries, and behind‑the‑scenes drama in the world of CART. What audiences got instead was a dizzying mix of digital car mayhem, melodramatic speeches, and physics‑defying crashes.Troy and Brad dig into the film's over‑the‑top action sequences, the baffling script choices, and one of the worst displays of “acting” this podcast has ever seen…. cough, cough - KIP! They also explore how the film's reputation has evolved, why some viewers have embraced its unintentional charm, and whether Driven deserves a second look or remains a cautionary tale about letting Stallone write his own sports movies.Buckle up, avoid the flying manhole covers, and prepare for a ride that makes absolutely no sense. This is one cinematic spinout worth revisiting.Want to help support the show? Head over to the Not A Bomb Tee Public store and check our merchandise. Special thanks to Ted Blair for the amazing designs!We're committed to hearing your feedback and suggestions. If there's a cinematic flop you'd like us to delve into, please reach out to us at NotABombPod@gmail.com or through our contact page. Your reviews and feedback are what drive us. If you enjoy our content, consider leaving a review on Apple Podcast or Spotify.Cast: Brad, Troy

Here's the Supporter-only Q&A from July 30th 2026. All comments and questions are fielded through the supporter service Q&A page.Please consider supporting this channel via monthly support services, tips, or even just by using our affiliate links to purchase things you were already going to buy anyway, at no extra cost to you:  https://www.retrorgb.com/support.htmlT-Shirts:  https://retrorgb.link/tshirtsAmazon Recommended List:  http://retrorgb.link/amazon TIMESTAMPS (please assume all links are affiliate / paid links that pay RetroRGB a commission on each sale.  Even if links are currently not affiliate, I may update them with one, should a partner list that item for sale in the future):00:00  Welcome!00:45  AES+ Output Info?:  https://retrorgb.com/new-official-neo-geo-aes.html 05:29  SMS to MK-2000 Converter:  https://retrorgb.com/sms.html08:42  RetroTINK plus Monitor BFI / Headphone Amp14:28  PVM + RetroTINK Setup, Dreamcast Video Issues20:11  SuperStation One Issues, VGA output, OLED Issues27:30  Cart setup for 12 consoles + CRT:  https://retrorgb.com/carts.html31:17  Genesis MiSTer Core Direct Video Issues32:52  Atari 7800 PSU34:14  Thank You:   https://www.retrorgb.com/support.html

As the marketing industry and the world at large continues to experience its own digital transformation, marketers have seen an explosion of channels, platforms, and of course data. To better understand the reality of today's marketing landscape and the tools at our disposal, we present our Tools of the Trade episode series. In this episode, we sit down with Mat Drela, retail media expert, author and path to purchase, 40 under 40 honoree at RMIQ, Red Door's exclusive retail media specialist partner. We cut through the hype to explain what retail media really is, why its closed loop measurement changes the game for challenger brands, and how the purchase data it generates can sharpen a brand's entire marketing plan. In this episode, we cover: What is retail media beyond Amazon? How does retail media close the loop? Why does retail media benefit challenger brands? Is ROAS enough to measure retail media success? How can retail media data shape brand strategy? Where do purchase signals add value? How should brands get started with retail media? Want to take the conversation further? Join us for our webinar, Click to Cart: How Retail Media Closes the Loop Between Ad & Sale, on Tuesday, August 25, at 10:00 a.m. PT.

ja entrou?http://orelo.cc/diariodebordo

Join Valerie Abraham as she shares how her upbringing in France, life in America, and marriage to her Egyptian American husband have shaped her unique approach to cooking and hospitality. From Sunday morning coffee and pastries to practical table décor on a budget (including dollar store dishes!), Valerie offers inspiring ideas, kitchen must-haves she uses daily, three favorite book recommendations, and a flavorful menu influenced by multiple cultures. She also reminds us that hospitality is an imitation of God, the ultimate giver of every good gift. We close with a moving, thought-provoking conversation about both giving and receiving hospitality during a season of grief. We're so glad you're here! Visit www.comeoverfordinner.com for recipes, product links, and more!

In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.   Key topics discussed included: The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma Treatment selection based on patient age, prior therapy, drug exposure, and disease biology The importance of shared decision-making and incorporating patient preferences into treatment planning Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care This episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/    Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology. #MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology

Welcome to Omni Talk's Retail Daily Minute, sponsored by R&S Logistics, Duvo and Mirakl.In today's Retail Daily Minute, Omni Talk's Chris Walton discusses:Ahold Delhaize USA partners with Pear Commerce to connect shoppable recipes and product discovery directly to online carts across Food Lion, GIANT, Giant Food, Hannaford, and Stop & Shop.Kroger rolls out a new AI Shopping Assistant across its banners, letting shoppers plan meals, build carts by budget and diet, and turn a photo or URL into a cart instantly.Macy's takes down its beloved red shopping bag billboard in Herald Square after more than 30 years, with new branding for the flagship promised soon.The Retail Daily Minute has been rocketing up the Feedspot charts, so stay informed with Omni Talk's Retail Daily Minute, your source for the latest and most important retail insights.

Send us Fan MailPediatric cancer is a gut punch most people can't look at for long, and that discomfort has a cost. We sit down with Dr Dean Lee, Professor of Pediatrics at The Ohio State University and Nationwide Children's Hospital, to talk about why kids' cancer research is still massively underfunded and why community-driven giving is not a feel-good extra. It's often the only way the next breakthrough gets its first chance.We unpack the hard truth behind the pediatric cancer funding gap: fewer patients means fewer commercial incentives, and “trickle-down” solutions from adult oncology don't always fit the diseases kids actually face. Dean explains why childhood cancer can be oddly invisible day to day, even though it remains a leading cause of death in children outside of accidents, and why foundations like Cancer Free Kids step in to fund the science that government grants won't touch early on.Then we get into hope with specifics. Dean walks us through what's changing in cancer immunotherapy and cellular therapy, including why CAR T cell therapy was a game-changer in leukemias and lymphomas and why solid tumors have been so much harder. We also talk about what pilot grants really do, how a $50,000 award can create the preliminary data needed for major funding, and a real example involving CRISPR and natural killer cell research that grew into a much bigger research platform.Join us for the third annual Little Legends Lemonade:

This month, the gals are joined by fellow podcaster and friend IRL Aaron Schoenrock to discuss clumsy robots, spilled hot sauce, Ohio's most awkward Chili's, nasty pro athletes, cadaver otters, and the grouchiest kitty in all of heaven. Tune in for July's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.  

More investigation into the strange sets of "cart ruts" we explored in the Phrygian Valley in Turkey. We show more drone footage and photos, look at examples of "cart ruts" from the "Oregon Trail" in Wyoming, as well as actual ruts in mud for comparison. We read more emails with suggestions and ideas and discuss them.Thank you all for your emails and comments! The ruts are a fascinating and enduring mystery.Support us on Patron or PayPal by going through our support page here: https://www.brothersoftheserpent.com/support

Originally aired 2/7/2023Introducing ZOUK'S CUBES – a new podcast from the creators of Add to Cart! Jason Mantzoukas is taking over the feed to bring Ku and Su on an unforgettable journey into the world packing cubes, pouches and backpacks. It's a meeting of the minds for Kulap, as her two besties Jason and SuChin hit it off at first, thanks to their shared love of wool socks and arch support. But things take a quick turn when Zouk's gear threatens the chaos Su thrives on. Forget everything you've heard so far, this is episode zero. Please note, Add To Cart contains mature themes and may not be appropriate for all listeners. To see all products mentioned in this episode, head to @addtocartpod on Instagram. To purchase any of the products, see below. Jason and Su share a deep love of Darn Tough SocksThe Birkenstock Zermatt slipper is so good, Jason bought severalThese small bags from Tom Bihn and Evergoods make going through TSA a breezeThis Evergoods backpack is carry-on and under-the-seat sizeBut wait, there's more backpacks: bellroy's Transit Backpack, and the Synik 30 and Shadow Guide 33 from Tom BihnThis Nitecore Powerbank can charge Jason's phone three times in one goThe stars of Zouk's Cubes are these Peak Design Packing CubesThe cherry on top of Jason's organizational system: little plastic baggiesCan't stand the Monopoly board game? Try the card game (pst, get the green pack)Jason nerds out about the Star Wars: Thrawn Series (and the Audible version too)See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Take a look at Joni's newest book: "Keeping Faith When Life Hurts." Order it here. --------Thank you for listening! Your support of Joni and Friends helps make this show possible. Joni and Friends envisions a world where every person with a disability finds hope, dignity, and their place in the body of Christ. Become part of the global movement today at www.joniandfriends.org. Find more encouragement on Instagram, TikTok, Facebook, and YouTube.

Picolé De Limão é um quadro do canal Não Inviabilize. Aqui você ouve as suas histórias misturadas às minhas!Use a hashtag #Protecao e comente a história no nosso grupo do telegram: https://t.me/naoinviabilizePUBLICIDADE MERCADO LIVRE Para todos os pais que falam que não precisam de nada, mas na verdade estão precisando de tudo: ofertas de até 70% OFF, até 21x sem juros com cartão Mercado Pago e muito mais só no Mercado Livre. Corre pro app fazer comprittas: https://bit.ly/4f7Umc5 Campanha válida até 09/08/2026. Cartão de crédito sujeito à aprovação. Parcelamento elegível a produtos selecionados. Veja condições do Vale Troca em mercadolivre.com.br/l/valetroca. Ver mais condições em Dia dos Pais.QUER OUVIR MAIS HISTÓRIAS? BAIXE NOSSO APLICATIVO EM SUA LOJA APPLE/GOOGLE, CONHEÇA NOSSOS QUADROS EXCLUSIVOS E RECEBA EPISÓDIOS INÉDITOS DE SEGUNDA A SÁBADO: https://naoinviabilize.com.br/assineEnvie a sua história bem detalhada para naoinviabilize@gmail.com, seu anonimato será mantido, todos os nomes, profissões e locais são trocados para preservar a sua identidade.Site: https://naoinviabilize.com.brTranscrição dos episódios: https://naoinviabilize.com.br/episodiosYoutube: https://youtube.com/naoinviabilizeInstagram: https://www.instagram.com/naoinviabilizeTikTok: https://www.tiktok.com/@naoinviabilizeX: https://x.com/naoinviabilizeFacebook: https://facebook.com/naoinviabilizeEdição de áudios: Depois O Leo Corta MultimídiaVinhetas: Pipoca SoundVoz da vinheta: Priscila Armani

There is some recent research that's testing out cancer treatments that can utilize the power of our immune systems to attack cancer cells. It's called CAR T-cell therapy and it involves programming immune cells to target and attack cancer in the body. Here to explain more is Dr. Shreya Shukla, a biomedical engineer specializing in this treatment. But first, host Dr. Samantha Yammine will separate hype from fact when it comes to one of the internet's most recent fixations: peptides. Later, Sam digs into a study trying to figure out how pigeons find their way home on a cloudy day. Link to Show Notes HERE Follow Curiosity Weekly on your favorite podcast app to get smarter with Dr. Samantha Yammine — for free! Still curious? Get science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. Terms apply. Hosted on Acast. See acast.com/privacy for more information.

Sam Harris speaks with Siddhartha Mukherjee about the science of cancer. They discuss the updated edition of The Emperor of All Maladies, whether cancer is one disease or many, why prevention is so hard, inflammation and air pollution as carcinogens, the myth that cell phones cause cancer, liquid biopsies and Bayesian reasoning, immunotherapy and CAR T cells, drug pricing, the promise of AI in drug discovery, the state of American medical science, and other topics. If the Making Sense podcast logo in your player is BLACK, you can SUBSCRIBE to gain access to all full-length episodes at samharris.org/subscribe.